Commercial Surrounded by controversy, FDA approves Biogen's Alzheimer's drug Aduhelm

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

-

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm, the very first Alzheimer’s medication in the last two decades, which is manufactured by Biogen Pharma.

“Aduhelm is an antibody that attacks the amyloid plaque that has been found to accumulate in the brains of people who have Alzheimer’s disease,” said Dr. Jeffrey Singer to The National Desk’s Jan Jeffcoat. “The only problem is that there’s still a lot of controversy among researchers as to whether or not those plaques are responsible for dementia or are a byproduct of some sort of another inflammatory process that’s causing dementia.”

The three executives of the expert committee of FDA have resigned in protest of Aduhelm’s approval. Dr. Singer said that the FDA has an expedited system for approval of drugs which makes these medications easily accessible by patients who may not have any time to wait.

Dr. singer claims that before 1962, FDA was only obliged to verify a drug’s safety and accurate labeling, not its efficacy.

Latest news

AstraZeneca and RQ Biotech enter into licensing agreement to develop antibodies against COVID-19

UK-based startup and British-Swedish pharma giant AstraZeneca have signed a licensing agreement amounting to over $150 million....

Kelun sells cancer drug development rights to Merck in a deal worth $1.4 billion

United States-based Merck & Co has made an addition to its cancer-fighting drugs after entering into a...

German Pharmaceutical and Medical Cannabis Products Distributor to be acquired by Franchise Global Health

The projected outcome of this acquisition is a boost in operations and the initiation of collaborations in...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you